Similar Papers

Paper Title
Journal
Date
Author
Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung ...
Cancer Research | VOL. 78
Hyun Cheol Chung, et. al.Hyun Cheol Chung ...
01 Jul 2018
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
Y Kubota ... K Shitara
ESMO Open | VOL. 8
Y Kubota, et. al.Y Kubota ... K Shitara
05 Jan 2023
Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.
Xiangdong Cheng ... Yian Du
Journal of Clinical Oncology | VOL. 42
Xiangdong Cheng, et. al.Xiangdong Cheng ... Yian Du
01 Jun 2024
Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
Rilan Bai ... Zheng Lv
Frontiers in oncology | VOL. 10
Rilan Bai, et. al.Rilan Bai ... Zheng Lv
21 Jul 2020
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto
E Felip ... S.-H Lee
Annals of Oncology | VOL. 36
E Felip, et. al.E Felip ... S.-H Lee
01 Feb 2025
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
FOxTROT: is anti-EGFR a good dancing partner?
Clara Montagut ... Joana Vidal
Annals of Oncology | VOL. -
Clara Montagut, et. al.Clara Montagut ... Joana Vidal
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.